ANN ARBOR, MICH. – August 31, 2022 – Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, is celebrating the 40th anniversary of its industry-leading Capiox brand of oxygenators.
This remarkable milestone is unmatched in the global oxygenator category.
Terumo’s Capiox oxygenators and their unique combination of lifesaving, leadership and technology has made them an industry leader for 40 years. Since the launch of the product line in 1982, Capiox oxygenators have become a global standard in patient care.
“In 1982, Terumo introduced the Capiox II oxygenator, the world’s first microporous hollow fiber membrane oxygenator, and has led the market in innovation ever since,” said Charlene Dusack, Senior Director, Global Marketing. “Through these 40 years, each successive product introduction in the Capiox line has focused on two critical aspects of an oxygenator - offering high performance for the operator and better outcomes for the patient.”
During their rich 40-year history, Terumo’s Capiox oxygenators have made a profound impact on healthcare. More than 2 million Capiox oxygenators have been manufactured to support critically ill heart patients around the world. Over the past four decades Capiox technology has continued to evolve and improve, with seven different families of oxygenators introduced to the marketplace. This legacy of innovation continues, with new Capiox technology in development and additional product launches planned for the future.
About Terumo Cardiovascular
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.